NCT05956847Recruiting
The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric Cancer: an Exploratory Multicenter Prospective Observational Clinical Study
Source: ClinicalTrials.gov · Last updated 29 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our understanding of tumor formation and evolution. The changes in ecDNA expression in intestinal type gastric cancer may be closely related to the occurrence and development of gastric cancer. Dynamic monitoring of changes in ecDNA expression in the gastric mucosa may help predict the occurrence of gastric cancer and guide subsequent treatment. By collaborating with multiple endoscopic centers to conduct gastroscopy biopsies on patients with gastric precancerous lesions, we aim to further explore the role of ecDNA in the occurrence and development of gastric cancer through continuous follow-up.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 7 Jul 2023
- Start date
- 10 Aug 2023
- Primary completion date
- 20 Jul 2028
- Lead sponsor
- Xijing Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05956847
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 10 Aug 2023 to the primary completion date, 20 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pathological results indicate other malignant tumors of the stomach, such as stromal tumors and lymphoma;
- Before gastroscopy or surgery, neoadjuvant therapy or combined with other malignant tumors;
- Non R0 resected gastric cancer patients;
- Have a history of drug abuse such as alcohol and tobacco.
Other
- The patient and their family members do not agree to use the specimen for later research projects;
- Pregnant or lactating women;
Who the study is looking for
- Age: 18-80 years old;
- Patients who plan to undergo gastroscopy at the endoscopic center and patients who undergo surgical treatment for gastric adenocarcinoma;
- Endoscopy doctors believe that pathological biopsy is necessary to clarify the pathological diagnosis;
- No serious diseases or other systemic malignancies in terms of physical and mental health;
- More than one item of non Atrophic gastritis, Atrophic gastritis, intestinal metaplasia, heterogeneous hyperplasia (low grade intraepithelial neoplasia and high grade intraepithelial neoplasia), and gastric adenocarcinoma;
- Sign an informed consent form;
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xijing Hospital of Digestive Diseases Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.